SCHEMBL30396708

SCHEMBL30396708

COC(=O)/C(=C/c1cc(F)c(F)cc1OC)N=[N+]=[N-]

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 1/20 0.34
▸ TUBB1 Q9H4B7 3/20 0.33
▸ NFE2L2 Q16236 3/20 0.32
▸ ALOX5 P09917 2/20 0.32
▸ STAT3 P40763 2/20 0.32
▸ PTGES O14684 1/20 0.32
▸ PTGS1 P23219 1/20 0.32
▸ LMNA P02545 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ APP P05067 1/20 0.31
▸ NFKB1 P19838 1/20 0.31
▸ NFKB2 Q00653 1/20 0.31
▸ RELA Q04206 1/20 0.31
▸ GAA P10253 1/20 0.30
▸ ADORA2A P29274 1/20 0.30
▸ ADORA2B P29275 1/20 0.30
▸ ADORA1 P30542 1/20 0.30
▸ MEN1 O00255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25764619 0.90 SMN1; SMN2 (0.34) TUBB1LMNAHTTRAB9AMEN1
SCHEMBL29015297 0.88 LMNA (0.35) KDM1ATUBB1NFE2L2ALOX5STAT3
SCHEMBL26312490 0.87 — —
SCHEMBL24113246 0.86 CTSL (0.38) LMNAHTTRAB9AAPPADORA2A
SCHEMBL30310695 0.86 CTSL (0.38) LMNAHTTRAB9AAPPADORA2A
SCHEMBL29015321 0.85 DPP4 (0.34) LMNAALDH1A1
SCHEMBL27891901 0.82 MAPT (0.48) NFE2L2MAPK1RAB9AMEN1ALDH1A1
SCHEMBL24113174 0.81 MAPT (0.46) LMNAHTTRAB9AGAAMEN1
SCHEMBL15871330 0.81 ADORA2A (0.41) NFE2L2LMNAHTTRAB9AADORA2A
SCHEMBL24113456 0.81 MAPT (0.38) LMNAGAAMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11952365-B2 Anti-viral compounds ALIGOS THERAPEUTICS, INC. (US) 2024-04-09 — — US disclosed
EP-4165037-A1 ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS Aligos Therapeutics, Inc. (US) 2023-04-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11952365-B2 Anti-viral compounds EIF2AK2, ZC3HAV1, HAVCR2 KDM1A 3554/4885TUBB1 2475/4885NFE2L2 2390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback